Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for dysphagia in ineffective esophageal motility
IRCT20210418051005N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of buspirone in Ineffective Esophageal Motility (IEM) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Mayo Score, Lower esophageal sphincter resting pressure and 2 more. Started Jun 2021; status: completed.
02
Drugs
buspirone
03
Conditions
Ineffective Esophageal Motility (IEM)
Beyond the preview
Go deeper on IRCT20210418051005N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210418051005N1.